Short-chain fatty acids for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with IgA nephropathy through a kidney biopsy.
- You are taking a stable dose of blood pressure medicines (ACE inhibitor or ARB) for at least 12 weeks.
- Your kidney function (eGFR) is at least 30 ml/min.
- You are willing to take the study supplement or placebo daily for the duration of the trial.
- You do not have diabetes or other major kidney diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
Hear when a new Primary IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.